PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Telix Pharmaceuticals Limited (TLX.AX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

AU000000TLX2

Sector

Healthcare

Highlights

Market Cap

A$9.06B

EPS (TTM)

A$0.16

PE Ratio

169.25

Total Revenue (TTM)

A$188.96M

Gross Profit (TTM)

A$123.88M

EBITDA (TTM)

A$15.75M

Year Range

A$10.34 - A$29.72

Target Price

A$25.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of A$10,000 in Telix Pharmaceuticals Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%40.00%50.00%SeptemberOctoberNovemberDecember2025February
37.92%
15.98%
TLX.AX (Telix Pharmaceuticals Limited)
Benchmark (^GSPC)

Returns By Period

Telix Pharmaceuticals Limited had a return of 10.69% year-to-date (YTD) and 147.41% in the last 12 months.


TLX.AX

YTD

10.69%

1M

2.44%

6M

39.55%

1Y

147.41%

5Y*

74.92%

10Y*

N/A

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of TLX.AX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202519.22%10.69%
202414.09%8.17%3.62%16.76%20.60%2.75%2.31%-2.46%11.39%0.96%18.20%-0.53%144.15%
2023-2.48%-1.55%-1.15%47.10%15.27%-4.10%0.62%-2.04%3.07%-22.46%14.03%0.00%38.65%
2022-12.39%-27.25%-15.38%10.29%1.08%-2.79%63.13%-16.10%-23.71%46.51%6.20%-1.22%-6.19%
20213.97%-2.54%11.75%-12.62%20.32%35.33%-7.55%20.60%-11.19%0.00%9.45%17.42%105.03%
2020-4.52%-11.49%-24.05%38.19%-0.00%-6.91%1.56%26.92%0.61%0.90%113.73%5.59%143.87%
201910.38%-0.35%17.48%3.57%21.26%17.54%13.71%-3.19%15.02%4.46%3.35%-8.55%138.46%
2018-9.68%-3.57%6.48%9.57%9.52%-2.90%-4.48%36.72%-5.71%1.82%-19.64%-3.70%4.84%
2017-15.97%-4.17%-19.48%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 97, TLX.AX is among the top 3% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TLX.AX is 9797
Overall Rank
The Sharpe Ratio Rank of TLX.AX is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of TLX.AX is 9595
Sortino Ratio Rank
The Omega Ratio Rank of TLX.AX is 9393
Omega Ratio Rank
The Calmar Ratio Rank of TLX.AX is 9999
Calmar Ratio Rank
The Martin Ratio Rank of TLX.AX is 9999
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Telix Pharmaceuticals Limited (TLX.AX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for TLX.AX, currently valued at 3.25, compared to the broader market-2.000.002.004.003.251.83
The chart of Sortino ratio for TLX.AX, currently valued at 3.81, compared to the broader market-6.00-4.00-2.000.002.004.006.003.812.47
The chart of Omega ratio for TLX.AX, currently valued at 1.47, compared to the broader market0.501.001.502.001.471.33
The chart of Calmar ratio for TLX.AX, currently valued at 8.88, compared to the broader market0.002.004.006.008.882.76
The chart of Martin ratio for TLX.AX, currently valued at 27.49, compared to the broader market-10.000.0010.0020.0030.0027.4911.27
TLX.AX
^GSPC

The current Telix Pharmaceuticals Limited Sharpe ratio is 3.25. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Telix Pharmaceuticals Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.504.00SeptemberOctoberNovemberDecember2025February
3.25
2.07
TLX.AX (Telix Pharmaceuticals Limited)
Benchmark (^GSPC)

Dividends

Dividend History


Telix Pharmaceuticals Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-15.00%-10.00%-5.00%0.00%SeptemberOctoberNovemberDecember2025February
-7.91%
-1.55%
TLX.AX (Telix Pharmaceuticals Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Telix Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Telix Pharmaceuticals Limited was 59.05%, occurring on May 12, 2022. Recovery took 235 trading sessions.

The current Telix Pharmaceuticals Limited drawdown is 7.91%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-59.05%Jan 17, 202280May 12, 2022235Apr 18, 2023315
-58.12%Nov 21, 201984Mar 23, 2020157Nov 2, 2020241
-41.75%Oct 22, 201836Dec 10, 2018116May 30, 2019152
-37.66%Nov 16, 201764Feb 19, 2018125Aug 17, 2018189
-32.8%Jun 23, 202386Oct 20, 2023102Mar 18, 2024188

Volatility

Volatility Chart

The current Telix Pharmaceuticals Limited volatility is 7.72%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%SeptemberOctoberNovemberDecember2025February
7.72%
3.32%
TLX.AX (Telix Pharmaceuticals Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Telix Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Telix Pharmaceuticals Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab